NCT01449721

Brief Summary

The purpose of this study is to assess the ability of an empiric resuscitation strategy compared to standard care to decrease the incidence of organ failure in normotensive sepsis patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
142

participants targeted

Target at P50-P75 for not_applicable sepsis

Timeline
Completed

Started Sep 2011

Longer than P75 for not_applicable sepsis

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

September 29, 2011

Completed
11 days until next milestone

First Posted

Study publicly available on registry

October 10, 2011

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2015

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2016

Completed
1.8 years until next milestone

Results Posted

Study results publicly available

October 4, 2017

Completed
Last Updated

October 4, 2017

Status Verified

October 1, 2017

Enrollment Period

3.3 years

First QC Date

September 29, 2011

Results QC Date

November 30, 2016

Last Update Submit

October 2, 2017

Conditions

Keywords

SepsisMultiple organ failureResuscitation

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Worsening Organ System Dysfunction Defined by SOFA Score Increase ≥ 1

    Development of worsening organ failure defined by the Sequential Organ Failure Assessment (SOFA) score. The SOFA score defines the presence and severity of dysfunction within 6 organ systems (cardiovascular, respiratory, coagulation, liver, renal, and nervous system) with a value of "0" for assigned to normal function to a maximum value of "4" for severe dysfunction in each of the organ systems. Each component of the SOFA score is added together, ranging from "0" indicating no organ dysfunction in any of the 6 organ systems, to "24" indicating maximal organ dysfunction across all 6 organ systems. Within this trial, the occurrence of organ failure was defined by any increase in the total SOFA score by ≥ 1 point over the first 72 hours after randomization.

    72 hours

Secondary Outcomes (2)

  • In-hospital Mortality

    In-hospital discharge or up to maximum 30 days

  • Number of Participants With Experiencing Complications Related to Intravascular Volume Overload

    12 hours following treatment initiation

Study Arms (2)

Control

NO INTERVENTION

Standard medical care by the primary treatment team.

Interventional arm

EXPERIMENTAL

Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization

Drug: Intravenous fluid

Interventions

0.9% Sodium chloride intravenous fluid

Also known as: Normal saline
Interventional arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Emergency department patient with suspected or confirmed infection as primary reason for admission
  • Serum venous lactate 2.0 - 3.9 mmol/L
  • Hospital admission planned

You may not qualify if:

  • Age \< 18 years
  • Pregnancy
  • Serum lactate ≥ 4.0 mmol/L
  • Any vasopressor or inotrope requirement
  • Mechanical ventilation or non-invasive positive pressure ventilation
  • Chronic end-stage renal disease requiring hemodialysis
  • Pulmonary edema as diagnosed by the primary care team
  • Requirement for surgery within the treatment protocol timeframe
  • Inability to obtain informed consent from subject or surrogate
  • Patient to receive comfort measures only

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Christiana Care Health System

Newark, Delaware, 19718, United States

Location

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

Location

Detroit Receiving Hospital/University Health Center

Detroit, Michigan, 48201, United States

Location

University of Mississippi Medical Center

Jackson, Mississippi, 39216, United States

Location

Cooper University Hospital:Cooper Medical School of Rowan University

Camden, New Jersey, 08103, United States

Location

Related Publications (3)

  • Sakr Y, Vincent JL, Schuerholz T, Filipescu D, Romain A, Hjelmqvist H, Reinhart K. Early- versus late-onset shock in European intensive care units. Shock. 2007 Dec;28(6):636-643.

    PMID: 18092378BACKGROUND
  • Mikkelsen ME, Miltiades AN, Gaieski DF, Goyal M, Fuchs BD, Shah CV, Bellamy SL, Christie JD. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009 May;37(5):1670-7. doi: 10.1097/CCM.0b013e31819fcf68.

    PMID: 19325467BACKGROUND
  • Glickman SW, Cairns CB, Otero RM, Woods CW, Tsalik EL, Langley RJ, van Velkinburgh JC, Park LP, Glickman LT, Fowler VG Jr, Kingsmore SF, Rivers EP. Disease progression in hemodynamically stable patients presenting to the emergency department with sepsis. Acad Emerg Med. 2010 Apr;17(4):383-90. doi: 10.1111/j.1553-2712.2010.00664.x.

    PMID: 20370777BACKGROUND

MeSH Terms

Conditions

SepsisMultiple Organ Failure

Interventions

Saline Solution

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShock

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Results Point of Contact

Title
Ryan Arnold, MD, Director of Research, Emergency Medicine
Organization
Christiana Care Health System

Study Officials

  • Alan Jones, MD

    University of Mississippi Medical Center

    STUDY CHAIR
  • Ryan Arnold, MD

    Cooper University Hospital: Cooper Medical School of Rowan University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 29, 2011

First Posted

October 10, 2011

Study Start

September 1, 2011

Primary Completion

January 1, 2015

Study Completion

January 1, 2016

Last Updated

October 4, 2017

Results First Posted

October 4, 2017

Record last verified: 2017-10

Locations